Site Search

Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.

Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

Academy Award-Winning Movie Director and Oklahoma Native Join the Cystic Fibrosis Foundation to Fight Fatal Disease

Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease

The CF Foundation’s “Adding Tomorrows” Video Selected From More Than 1,000 entries; To Be Featured on YouTube’s Homepage

Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments

Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments